Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2010. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity transaction rather than general financial performance.
Material Changes
The only material change reported is an increase in the interest of Mr. D J Phelan in Ordinary share ADRs. This transaction occurred on April 13, 2010, following the re-investment of the dividend paid to shareholders on April 8, 2010.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a regulatory disclosure of a director's shareholding change.
Important Facts for Investors
- Transaction Date: April 13, 2010.
- Individual: Mr. D J Phelan.
- Transaction Type: Increase in interest in Ordinary share ADRs via dividend re-investment.
- Price: $38.86 per ADR.
- Resulting Interest: 269.05 ADRs.
- Regulatory Basis: Notification in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).